Tocagen (NASDAQ:TOCA) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Friday.
A number of other analysts have also recently commented on the stock. BidaskClub raised shares of Tocagen from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Zacks Investment Research raised shares of Tocagen from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $23.67.
Shares of Tocagen (NASDAQ:TOCA) traded down $0.91 during midday trading on Friday, hitting $12.48. 90,010 shares of the company traded hands, compared to its average volume of 147,157. The company has a debt-to-equity ratio of 0.07, a quick ratio of 6.03 and a current ratio of 6.03. Tocagen has a one year low of $8.60 and a one year high of $17.95.
A number of hedge funds and other institutional investors have recently bought and sold shares of TOCA. EcoR1 Capital LLC purchased a new position in shares of Tocagen in the 2nd quarter worth approximately $18,074,000. FMR LLC acquired a new stake in Tocagen during the 2nd quarter valued at approximately $9,624,000. Vanguard Group Inc. acquired a new stake in Tocagen during the 2nd quarter valued at approximately $5,036,000. JPMorgan Chase & Co. acquired a new position in shares of Tocagen in the 2nd quarter valued at $4,960,000. Finally, Pure Financial Advisors Inc. acquired a new position in shares of Tocagen in the 4th quarter valued at $1,324,000. 36.96% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/04/tocagen-toca-upgraded-to-sell-at-valuengine.html.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.